Weight Loss

Wegovy vs Ozempic vs Mounjaro vs Zepbound: Which GLP-1 Is Right for You?

If you have been reading about weight loss medications in the news, you have probably come across names like Ozempic, Wegovy, Mounjaro, and Zepbound. These belong to a class of medications called GLP-1 receptor agonists, and they have changed the way physicians approach weight management.

GLP-1 stands for glucagon-like peptide-1. Your body produces this hormone naturally. It helps regulate blood sugar after meals, slows digestion so food stays in your stomach longer, and sends signals to your brain that reduce appetite. GLP-1 medications work by mimicking this hormone at higher, more sustained levels than your body produces on its own.

The result is that many patients feel genuinely less hungry. Not in a jittery, stimulant-driven way, but in a quieter way. The constant background noise of food cravings gets turned down. For patients who have struggled with portion control or late-night eating despite real effort, this can feel like a fundamental shift.

The way this plays out in practice is worth explaining. When you eat a meal, your stomach normally empties at a certain rate. GLP-1 medications slow that process down, which means food stays in your stomach longer and you feel full sooner. At the same time, these medications act on receptors in the brain that regulate appetite and reward signaling around food. It is not willpower. It is biochemistry, and for many patients this is the piece that was missing from previous weight loss attempts.

GLP-1 medications also have meaningful effects on blood sugar regulation, which is why some of them were originally developed for type 2 diabetes. For patients who have insulin resistance or prediabetes alongside their weight concerns, these medications can address both issues simultaneously.

There are currently four brand-name GLP-1 medications commonly prescribed for weight management. They fall into two molecular families, and understanding that distinction is the key to making sense of the whole landscape.

This is the single most common source of confusion, so let's clear it up directly. Wegovy and Ozempic are the same molecule: semaglutide. They are made by the same manufacturer (Novo Nordisk). The difference is the FDA approval and the dosing.

Ozempic is FDA-approved for type 2 diabetes management. It is prescribed at doses up to 2 mg per week. Many patients taking Ozempic for diabetes notice weight loss as a side effect, and this is what initially generated public interest in semaglutide for weight management.

Wegovy is FDA-approved specifically for chronic weight management. It uses the same semaglutide molecule but at a higher maximum dose of 2.4 mg per week. The clinical trials for Wegovy (the STEP trials) showed average weight loss of approximately 15% of body weight over 68 weeks when combined with lifestyle changes.

In practical terms, the distinction matters primarily for insurance coverage. An insurance plan that covers Wegovy for weight loss may not cover Ozempic for that same purpose, since Ozempic's approved indication is diabetes. Your physician can help you determine which version makes more sense given your medical history and insurance situation.

Both Wegovy and Ozempic are administered as once-weekly injections using a pre-filled pen. The injection is subcutaneous (just under the skin, typically in the abdomen or thigh) and most patients find it straightforward after the first time. Side effects are similar for both, since the active ingredient is identical.

Dosing follows a gradual escalation schedule over several months. For Wegovy, patients typically start at 0.25 mg per week and increase every four weeks through 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg. This slow ramp-up helps your body adjust and reduces the severity of side effects. Ozempic follows a similar pattern but tops out at 2 mg.

One thing patients often ask is whether Ozempic can be prescribed "off-label" for weight loss if their insurance will not cover Wegovy. The answer is yes, physicians can prescribe medications off-label, and this is a common practice. However, insurance coverage for off-label use is not guaranteed. This is one of the practical details Dr. Gougian helps patients sort through during their initial consultation.

The same pattern applies here. Zepbound and Mounjaro are the same molecule: tirzepatide, manufactured by Eli Lilly.

Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. Same drug, different approved uses, different insurance pathways.

What makes tirzepatide different from semaglutide is that it works on two receptors instead of one. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism appears to produce somewhat greater weight loss on average compared to semaglutide alone.

The SURMOUNT clinical trials showed that patients on the highest dose of tirzepatide lost an average of approximately 21% of their body weight over 72 weeks. That is a meaningful difference from the 15% seen with semaglutide, though individual results vary significantly. Some patients respond very well to semaglutide and less well to tirzepatide, and vice versa.

Like semaglutide, tirzepatide is a once-weekly injection. The side effect profile is broadly similar, with gastrointestinal effects (nausea, especially during dose escalation) being the most common complaint.

The GIP receptor involvement is what researchers believe drives the additional weight loss. GIP plays a role in how your body stores and uses fat, and activating both receptors at once appears to create a stronger metabolic effect than GLP-1 activation alone. This is still a relatively new area of research, but the clinical trial data has been consistent.

Tirzepatide dosing also escalates gradually, starting at 2.5 mg per week and increasing through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to 15 mg. The escalation takes longer than semaglutide because there are more dose steps. Patients and their physicians can also decide to stay at a lower maintenance dose if they are seeing good results without the side effects that sometimes come with higher doses.

Here is a straightforward comparison of all four medications. Keep in mind that "average weight loss" figures come from clinical trials where participants also followed a reduced-calorie diet and increased physical activity.

The table helps clarify the landscape, but it does not tell the whole story. Which medication works best for a given patient depends on factors that do not fit neatly into a chart: your metabolic profile, your insurance coverage, how your body responds to the medication during the dose escalation period, and whether you have other conditions like type 2 diabetes that might make one option clinically preferable.

It is also worth noting that the clinical trial weight loss numbers represent averages. Some patients lose significantly more than the average. Others lose less. Your starting weight, your metabolic health, how consistently you take the medication, and whether you make nutritional and activity changes alongside the medication all affect your individual results.

One practical difference that matters for many patients: availability. Supply shortages have affected both semaglutide and tirzepatide products at various points. If one medication is on backorder at your pharmacy, your physician may need to switch you to an alternative or adjust your dosing. Having a physician who understands all four options and can pivot when supply issues arise is one of the advantages of working with a practice like Pandora Family Medicine rather than a single-product platform.

This is the question patients most want answered, and the honest answer is that it depends on your specific situation. Here is how Dr. Gougian typically approaches this conversation at Pandora Family Medicine.

If you have type 2 diabetes and want to lose weight, Mounjaro or Ozempic may make sense because they are approved for diabetes, which often means better insurance coverage. Mounjaro's dual mechanism may offer advantages for blood sugar control alongside weight loss.

If weight loss is your primary goal and you do not have diabetes, Wegovy or Zepbound are the FDA-approved options. Zepbound may produce greater average weight loss due to its dual-receptor mechanism, but availability and insurance coverage vary. Wegovy has been on the market longer and may be easier to obtain through some pharmacies.

If cost is a primary concern, this is an important factor. The list prices for all four medications are high (often over $1,000 per month without insurance). Insurance coverage varies widely by plan and by medication. At Pandora Family Medicine, we help patients navigate prior authorization for the medication that makes the most clinical sense. If insurance coverage is not available, we discuss the realistic out-of-pocket costs and whether a different approach might be more sustainable.

If you tried one and it did not work well, switching between the two molecular families is a reasonable step. A patient who experienced significant nausea on semaglutide (Wegovy or Ozempic) may tolerate tirzepatide (Zepbound or Mounjaro) differently, or vice versa. A patient who saw limited weight loss on one may see better results on the other. This is one of the reasons physician-guided weight management matters. An algorithm cannot adjust your plan the way a physician who knows your history can.

If you have a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, GLP-1 medications are not appropriate. This is a firm contraindication based on animal studies. Dr. Gougian screens for these conditions as part of your initial evaluation.

What all four medications share is that they work best as part of a broader plan. They reduce appetite, but they do not replace nutritional awareness, regular movement, or the metabolic monitoring that helps your physician adjust your treatment over time. At Pandora Family Medicine, Dr. Gougian incorporates lab work, metabolic health assessments, and follow-up visits into every weight loss plan.

At Pandora Family Medicine, weight loss visits follow a straightforward structure. Your initial visit costs $200, and follow-up visits are $150. There is no monthly subscription fee, no mandatory program enrollment, and no platform charge on top of your medication cost. You see Dr. Gougian directly, not a rotating team of providers.

This is a different model from telehealth weight loss services like Ro, Noom, or Calibrate, which charge monthly platform fees in addition to the cost of the medication itself. At Pandora, you pay for physician visits. That is it.

Your first visit includes a thorough review of your medical history, current medications, and weight loss goals. Dr. Gougian will order baseline lab work (drawn on-site at our in-office lab) and discuss which medication, if any, makes sense for your situation. Not every patient is a candidate for GLP-1 medications, and not every candidate needs them. Some patients do better with a different approach entirely.

If a GLP-1 medication is appropriate, we handle the prior authorization process for patients who want to use insurance. If your insurance does not cover the medication, we will discuss cash-pay options and help you make an informed decision about whether the out-of-pocket cost makes sense for your circumstances.

Dr. Gougian is a Diplomate of the American Board of Obesity Medicine. Weight management is not a sideline service here. It is a core part of what this practice does, and every treatment plan is built around your labs, your history, and your goals.

Related Articles